Fiche centre
University of California, Irvine
Orange — United States
Essais liés10clinical trials
VilleOrangelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06798896
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| SPN-817 | Épilepsie | Phase 2 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | RECRUITING |
| rondecabtagene autoleucel | SEP | Phase 3 | NCT07188558 | PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | RECRUITING |
| GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | Myopathies | À vérifier | NCT05257473 | GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| GRASP-01-003 — LGMD R1 Natural History Study | Myopathies | À vérifier | NCT05618080 | GRASP-01-003 — LGMD R1 Natural History Study | ACTIVE_NOT_RECRUITING |
| Descartes-08 | Myopathies | Phase 2 | NCT07391605 | Descartes-08 in Autoantibody Myositis | RECRUITING |
| CNP-106 | Myasthénie | Phase 1/2 | NCT06106672 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Standard lymphodepletion regimen | Myasthénie | Phase 2/3 | NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | RECRUITING |
| Mexiletine | Sclérose latérale amyotrophique | Phase 2 | NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
| eculizumab | Myasthénie | Phase 2 | NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | TERMINATED |